Deals and Financings

• China's Hansoh Pharma formed an AI-based small molecule drug discovery collaboration worth up to $1.5 billion with Atomwise of San Francisco; 
• Shanghai Henlius Biotech, the biologics arm of Fosun Pharma, will price its Hong Kong IPO to raise as much as $477 million, valuing Henlius at $3.5 billion; 
• Insilico Medicine, a Hong Kong AI-based drug discovery company, closed a $37 million Series B funding round led by Qiming Venture Partners; 
• SoliPharma of Hangzhou completed a $36.5 million financing to support its development of high-end, difficult-to-make generic drugs;
• Zhejiang Jiuzhou Pharma, an API company, will pay $16 million to acquire PharmAgra Labs of North Carolina, an API CRO/CDMO business;
• Genenta Science of Milan raised $14.6 million in its third funding to develop gene therapies for cancer using autologous hematopoietic stem progenitor cells;
• Stroke Medical of Shanghai completed a $14 million B financing to develop devices that prevent strokes and others that open clogged blood vessels; 
• China's Laviana Pharma raised $14 million in a B+ financing to develop its CDMO operations;

Trials and Approvals

• Gracell, a Suzhou-Shanghai biotech, reported positive early results of its first-in-class FasT CAR-19 cell gene therapy in patients with B-ALL leukemia; 
• Cellular Biomedicine launched a China Phase II trial for AlloJoin®, its stem cell treatment for knee osteoarthritis; 
• I-Mab Biopharma of Shanghai will collaborate with Junshi to test I-Mab's CD73 antibody together with Junshi's China-approved PD-1 drug;
• Sichuan Clover Biopharma started a China Phase I trial of its fully-human TRAIL-Trimer fusion protein in patients with peritoneal carcinomatosis; 
• CANbridge Pharma of Shanghai received China Priority Review status for Hunterase to treat Hunter syndrome, a rare disease;

Company News

• JHL, a Taiwan-China biotech, settled an IP suit brought by Genentech by agreeing to stop development of biosimilars to Genentech drugs;
• AstraZeneca and the Wuxi municipal government opened a new high-tech park expected that will eventually house 50 innovative life science companies.